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Summary
Neuropeptide Y (NPY) is a potent orexigenic neuropeptide, and antagonism of NPY Y1 and NPYY5 receptors (NPYxR) is con-
sidered a potentially important anti-obesity drug target. We tested the hypothesis that blockade of the NPY5R will lead to
weight loss in humans using MK-0557, a potent, highly selective, orally active NPY5R antagonist. The initial series of exper-
iments reported herein, including a multiple-dose positron-emission tomography study and a 12 week proof-of concept/
dose-ranging study, suggested an optimal MK-0557 dose of 1 mg/day. The hypothesis was then tested in a 52 week, multi-
center, randomized, double-blind, placebo-controlled trial involving 1661 overweight and obese patients. Although statisti-
cally significant at 52 weeks, the magnitude of induced weight loss was not clinically meaningful. These observations pro-
vide the first clinical insight into the humanNPY-energy homeostatic pathway and suggest that solely targeting theNPY5R in
future drug development programs is unlikely to produce therapeutic efficacy.Introduction
Since the initial observation over two decades ago that neuro-
peptide Y (NPY) was a potent orexigenic factor (Clark et al.,
1984), numerous pharmacological (Stanley et al., 1992; Gerald
et al., 1996; Hu et al., 1996; Cabrele et al., 2000; Mullins et al.,
2001; Parker et al., 2000) and neuroanatomical studies (Saw-
chenko, 1998; Elias et al., 1998, 1999; Cowley et al., 1999; Kishi
et al., 2005) have implicated the NPY system as a prominent
anabolic pathway that promotes positive energy balance in
mammals. The NPY neuron in the arcuate nucleus of the hypo-
thalamus and NPY Y1 and Y5 receptors (NPY1R and NPY5R) in
the arcuate nucleus and adjacent regions of the hypothalamus
are believed to be critical components of a pathway that func-
tions to stimulate food intake and decrease energy expenditure
(Kalra et al., 1999; Schwartz et al., 2000). Consistent with its pro-
minent central regulatory role in energy homeostasis, NPY
synthesis and release by the NPY neuron are controlled by hor-
mones that transmit the status of peripheral energy stores, in-
cluding insulin, leptin, ghrelin, and peptide YY (Schwartz et al.,
1992; Stephens et al., 1995; Baskin et al., 1999; Batterham
et al., 2002; Willesen et al., 1999; Dickson and Luckman,
1997; Kumarnsit et al., 2003).CELL METABOLISM 4, 275–282, OCTOBER 2006 ª2006 ELSEVIER INCGenetic studies have also been performed to investigate the
role of NPY and its receptors in energy homeostasis. However,
the results of those studies have been inconsistent and a source
of controversy. NPY knockout (NPY2/2) mice have normal food
intake and body weight, although NPY2/2 mice bred to ob/ob
leptin-deficient mice demonstrate partial reduction of the ob/ob
obese phenotype (Erickson et al., 1996a, 1996b). NPY1R2/2
mice have only slightly diminished spontaneous and NPY-
stimulated feeding and develop late-onset mild obesity (Pedraz-
zini et al., 1998; Kushi et al., 1998). Similarly, NPY5R2/2 mice
feed normally and develop late-onset mild obesity (Marsh et al.,
1998). A recent study that employed a diphtheria toxin-mediated
cell knockout strategy that targeted arcuate nucleus NPY neu-
rons suggested that developmental compensation might ac-
count for the relatively small impact observed in previous genetic
ablation studies (Luquet et al., 2005).
Collectively these observations suggest that antagonism of
the central NPY system may be an attractive strategy for the
pharmacological treatment of obesity. Indeed, significant efforts
to develop antagonists to the NPY1R and NPY5R for the treat-
ment of the growing obesity pandemic have been underway in
the pharmaceutical industry for a number of years (Parker
et al., 2002). However, to date the efficacy of such an approach. DOI 10.1016/j.cmet.2006.08.002 275
A R T I C L Ehas been untested in humans. In the present report we present
the results of preclinical and clinical studies aimed at testing the
hypothesis that antagonism of the NPY5R leads to weight loss
in overweight and obese patients.
Results
Preclinical studies
MK-0557, trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro
[6 azaisobenzofuran-1(3H),10-cyclohexane]-40-carboxamide, is
an orally available NPY5R antagonist (Figures 1 and 2A) (Fukami
et al., 2004). Displacement studies using the NPY receptor
radioligands [125I]-peptide YY (PYY) or [125I]-pancreatic poly-
peptide (PP) and cloned receptors expressed in heterologous
cell lines demonstrate that MK-0557 has a Ki = 1.3 nM at the
human NPY5R, with similar affinities at rhesus, mouse, and rat
NPY5R (Table 1). MK-0557 has no significant binding to the
human NPY1R, NPY2R, NPY4R, or mouse NPY6R at concentra-
tions of 10 mM. These data indicate a >7500-fold selectivity for
the NPY5R relative to the other NPY receptor subtypes.
An in vitro screen of 183 receptors, enzymes, and ion chan-
nels (MDS Pharma Services) revealed activity at only three
proteins; Ki values for MK-0557 binding to the adenosine A1 re-
ceptor, the serotonin 5-HT2B receptor, and the monoamine
transporter were 0.73, 0.91, and 0.23 mM, respectively. How-
ever, subsequent in vitro studies failed to demonstrate physio-
logically relevant activity of MK-0557 at these three receptors.
Thus, to the extent testable, these studies suggest that MK-
0557 should not have significant off-target activity in vivo.
MK-0557 antagonized the effects of the NPY5R-selective
agonist, D-Trp34NPY, on body-weight gain and hyperphagia in
C57BL/6J mice and significantly suppressed the body-weight
gain in diet-induced obese (DIO) mice (Figure 2B). When lean
mice on regular chow were switched to a medium high-fat diet
(4.2 kcal/g) (Oriental BioService: 53.4% energy as carbohydrate,
15.3% as protein, and 31.3% as fat) and treated with MK-0557
at 30 mg/kg PO QD, the compound caused a 40% reduction in
body-weight gain at day 35 (p < 0.05 versus control). This body-
weight change was accompanied by a reduction of retroperito-
neal fat pad weight of about 30% (p < 0.05), a reduction of epi-
didymal and mesenteric fat pad weights of about 22% (p > 0.05),
and a reduction in leptin levels by 36% (p < 0.05). Cumulative
food intake was also reduced by about 5% compared to con-
trols (p > 0.05).
Another highly selective NPY5R antagonist, L-152804, which
inhibits high-fat-diet-induced weight gain, has been shown to
act through the NPY5R since it had no effect in NPY5R2/2
mice (Ishihara et al., 2006). L-152804 was also used to demon-
strate the efficacy of NPY5R antagonism to induce weight loss in
a nonhuman primate (rhesus macaque) DIO model (MacNeil
et al., 2006). On the basis of these preclinical observations,
clinical studies were initiated with MK-0557.
Phase I single-dose study
A phase I rising dose study examined single oral doses of MK-
0557 from 10 mg up to 750 mg or matching placebo adminis-
tered to two alternating eight-subject panels (six active and
two placebo subjects/panel) of healthy normal young men. No
clinically significant abnormalities were noted in routine serum
chemistry, CBC, urinalysis, ECG, and physical examinations.
Fifteen subjects reported a total of 35 clinical adverse events276(AEs) (27 while on MK-0557; 8 while on placebo), none of which
was serious or resulted in study discontinuation. Three of the
adverse experiences (headache [1], frontal headache [2]) were
classified as drug related by the investigator; all were rated as
mild in intensity and all symptoms resolved spontaneously. The
mean apparent plasma half-life was approximately 24 hr, while
the AUC0-N and Cmax at the 10 mg dose were 2.8 mM  hour and
0.07 mM, respectively. Pharmacokinetic data from the rising
dose study can be found as Figure S1 and Table S1 online.
Positron emission tomography study
An NPY5R-selective positron emission tomography (PET) li-
gand, [11C]MK-0233, which had been developed and validated
in rhesus monkey, was used to perform a receptor occupancy
study in human volunteers. [11C]MK-0233 has a similar structure
to MK-0557 (Figure 1) and is also highly selective for the NPY5R.
NPY5R occupancies 24 hr after a single oral 125, 5, or 1.25 mg
dose of MK-0557 were (mean6 SD) 107%6 5%, 105%6 3%,
and 98% 6 5%, respectively, relative to predose baseline
(Panels A, B, and C; Figure 3). Five days after dosing with
5 mg, receptor occupancy was still high in the three subjects
in Panel D (Figure 3), with a mean (6SD) receptor occupancy
of 69% 6 24%. Receptor occupancy in the placebo subjects
was 3% 6 9%. The predicted concentration required to have
90% receptor occupancy was 4.3 nM (95% CI: [2.6, 7.2]). These
data indicated that essentially complete receptor occupancy
could be obtained by a relatively small, once daily dose of MK-
0557. This conclusion was further tested in a proof-of-concept/
dose-ranging study.
Proof-of-concept/dose-ranging study
This multicenter, double-blind, randomized, placebo-controlled
study examined the weight-loss efficacy and tolerability of
MK-0557 versus placebo. The study included a 6 week diet and
exercise run-in, the last 2 weeks of which subjects were dosed
a single-blind placebo, followed by a 12 week randomized on-
drug treatment period and a 12 week off-drug follow-up period.
Figure 1. Structures of MK-0557 and PET ligand [11C]MK-0233
MK-0233 has an N in a different ring position in ring 1, a 5-member ring has been
replaced with 6-member ring.
Table 1. MK-0557 binding affinity at the neuropeptide Y Y5 receptor
Human Rhesus Mouse Rat
MK-0557 1.3 6 0.05 0.79 6 0.16 0.74 6 0.2 1.4 6 0.1
PYY 2.9 6 0.7 n.d. 0.82 6 0.07 0.51 6 0.15
Data represent mean6 SEM (n =3); n.d. not done. Human, rhesus, mouse, and rat
NPY5R expressed in LMtk, COS-7, CHO, and COS-7 cells, respectively.CELL METABOLISM : OCTOBER 2006
NPY5R antagonism lacks anti-obesity efficacyThe study randomized 547 subjects to placebo or 0.2, 1, 5, or
25 mg MK-0557 in a 1:1:1:1:1 ratio; 402 subjects completed
the 12 week treatment period and 354 subjects completed the
entire study. Patient discontinuations were approximately equal
across all treatment groups. The primary analysis population
was a modified intention to treat (MITT) population, which
was composed of subjects who received at least one dose of
randomized study medication and had at least one post-
randomization/baseline weight measurement.
The weight loss results are summarized in Figure 4 and
Table 2. In the MITT population, after 12 weeks, the mean
change from baseline was 20.6, 21.3, 21.9, 21.7, and
22.0 kg for subjects treated with placebo or 0.2, 1, 5, and
25 mg MK-0557, respectively. There was a statistically signifi-
cant dose-response trend across placebo, 0.2 mg and 1 mg
(p < 0.001), and the 1, 5, and 25 mg dose groups were signifi-
cantly different from placebo (p% 0.001); the 0.2 mg dose group
was marginally significantly different than placebo (p = 0.054).
The 1, 5, and 25 mg dose groups were not significantly different
from each other, consistent with a plateau in the dose-response
curve. Among subjects completing the 12 week treatment period
with no major protocol violations, the mean change from base-
line to 12 weeks was 20.7, 21.6, 22.2, 22.1, and 22.3 kg for
those on placebo or 0.2, 1, 5, and 25 mg MK-0557, respectively.
In this population, all dose groups were significantly different
Figure 2. Effects of MK-0557 on intracellular calcium and weight gain in mice
A) Effect of MK-0557 on NPY-induced increase in intracellular calcium concentra-
tion in CHO cells expressing the human NPY5R. Data represent mean 6 SEM
(n = 4).
B) D-Trp34NPY-induced body-weight gain in C57BL/6J mice after chronic oral
dosing of MK-0557. 5 mg/day of D-Trp34NPY infused ICV, ( ) represents no. of
animals. Data shown as mean 6 SEM, ##p < 0.01 versus PBS-infused control,
*p < 0.05 versus vehicle-treated control (ANOVArep and Bonferroni/Dunn test).CELL METABOLISM : OCTOBER 2006from placebo (p % 0.001 for 1, 5, and 25 mg, and p = 0.036
for 0.2 mg). In subjects who entered the off-drug phase, the
weight loss experienced during the 12 week treatment phase
was generally maintained. There were no significant changes
in insulin-, leptin-, or obesity-related comorbidity endpoints,
including BP, fasting plasma glucose, total cholesterol, HDL-
cholesterol [HDL-C], LDL-cholesterol [LDL-C], or triglycerides
[TG].
No drug-related serious AEs occurred and there were no sig-
nificant differences in AEs in any organ system for any dose
of MK-0557 compared to placebo. There were no significant
changes in QTc, serum chemistry profile, CBC, urinalysis, corti-
sol, prolactin, IGFBP-3, or TSH. Serum IGF-I increased approx-
imately 20% relative to placebo in the 1, 5, and 25 mg dose
groups (p % 0.004). Screening demographics, a patient-
accounting summary, and additional data on efficacy endpoints
and clinical and laboratory adverse events can be found as
Tables S2–S7.
The results of the proof-of-concept/dose-ranging study dem-
onstrated that MK-0557 induces modest weight loss in obese
Figure 3. PET ligand study
Upper: Summed PET images in the interval 60–90 min for the different doses of
MK-0557. Lower: Estimated relationship between receptor occupancy and plasma
concentration using Emax model. The vertical line represents the limit of quantita-
tion (LOQ) of the assay; values below LOQ were extrapolated from last available
plasma concentration. The solid line represents estimated mean; dashed lines
represent 95% confidence bands. Predicted EC95 (95% CI) = 6.5 (3.5, 12.3) nM.
PD, post-dose.277
A R T I C L Eindividuals over 12 weeks and is generally safe and well toler-
ated. The dose-response trend in weight loss observed in this
study was generally similar to the dose response in PET receptor
occupancy, in that there was a dose-response trend in body-
weight loss and receptor occupancy across placebo, 0.2, and
1 mg, but there was a plateau observed in body-weight loss
and receptor occupancy at 1 mg and above. These results
were supportive of using 1 mg in future studies. Since there
was no evidence of a plateau (over time) in the weight loss
over the 12 week treatment period, it was hypothesized that
continued weight loss might be observed over a longer treat-
ment period and a long-term study with MK-0557 1 mg qd
was, therefore, initiated.
Long-term weight-loss study
This was a multicenter, double-blind, randomized, placebo-
controlled study to examine the safety and efficacy of MK-
0557 to induce weight loss in obese patients. The primary hy-
pothesis was that MK-0557 was more effective than placebo
at inducing weight loss after 52 weeks of treatment. The study
included a 2 week diet and exercise run-in in which patients
were administered placebo in a single-blinded manner. A total
of 1661 patients were randomized in a 1:2 ratio to placebo or
1 mg MK-0557; 1555 patients were included in the MITT analysis
population (106 patients were excluded due to a lack of post-
baseline data). There were 832 patients who completed the
study without major protocol violations (approximately 49% of
patients randomized to placebo and 51% of patients random-
ized to MK-0557). Similar to the 12 week study, the primary anal-
ysis was conducted in a MITT population. After 52 weeks, the
mean change from baseline (95% CI) for the MITT population
was 21.1 (21.5, 20.6) kg and 22.2 (22.5, 1.8) kg for patients
on placebo and 1 mg MK-0557, respectively; the difference be-
tween the treatment groups was significant (p < 0.001) (Figure 5;
Table 2). Among patients finishing the 52 week treatment period
without major protocol violations, the mean weight loss from
baseline was 21.8 (22.6, 21.0) and 23.4 (24.0, 22.8) kg for
patients on placebo and 1 mg MK-0557, respectively; the differ-
Figure 4. Change in body weight during the proof-of-concept study/dose-ranging
study
yLS mean estimates and 84% CI based on ANCOVA model with terms for treat-
ment weight change. 84% CI on the observed means shown at week 12. Last ob-
servation carried forward; LS = least squares; CI = confidence interval.278ence between groups was statistically significant (p < 0.001).
The percent of 5% responders (i.e., those who lostR5% of their
baseline body weight) was 17.5% and 23.3% for patients
treated with placebo and MK-0557, respectively; the adjusted
odds ratio (95% CI) of 1.5 (1.1, 2.0) was significant (p = 0.006).
The percent of 10% responders (i.e., those who lost R10% of
their baseline body weight) was 5.6% and 8.7% for patients
treated with placebo and MK-0557, respectively; the adjusted
odds ratio (95% CI) of 1.7 (1.1, 2.6) was significant (p = 0.022).
For waist circumference, the mean difference (95% CI) be-
tween groups in change from baseline was 21.1 (21.6, 20.3)
cm in the MITT population at week 52 (p = 0.003). There were
no significant differences observed in total cholesterol, HDL-
C, LDL-C, TG, FPG, insulin, or systolic or diastolic blood pres-
sure between MK-0557 and placebo in the MITT population
after 52 weeks of treatment. At week 52 there was no significant
difference between MK-0557 and placebo in the number of
patients who had metabolic syndrome as defined by NCEP
ATP III criteria (p = 0.708) (http://www.nhlbi.nih.gov/guidelines/
cholesterol/atglance.htm).
Among the 5% responders, there were no significant differ-
ences between groups observed in HDL-C, TG, systolic blood
pressure, glucose, or waist circumference. A nominally signifi-
cant increase in diastolic blood pressure was observed in the
Table 2. Summary of weight changes in the clinical studies
Least Squares (LS)
Mean (95% CI) MITT
Per Protocol
Completers
Proof-of-concept/dose-ranging studya
Placebo 20.6 (21.1, 20.1) 20.7 (21.3, 20.0)
0.2 mg 21.3 (21.8, 20.8) 21.6 (22.3, 21.0)
1 mg 21.9 (22.4, 21.4) 22.2 (22.9, 21.5)
5 mg 21.7 (22.3, 21.2) 22.1 (22.7, 21.4)
25 mg 22.0 (22.5, 21.4) 22.3 (23.0, 21.7)
Long-term studyb
Placebo 21.1 (21.5, 20.6) 21.8 (22.6, 21.0)
1 mg 22.2 (22.5, 1.8) 23.4 (24.0, 22.8)
a 12 weeks of treatment.
b 52 weeks of treatment.
Figure 5. Change in body weight during the long-term study
yLS mean estimates and 84% CI based on ANCOVA model with terms for treat-
ment, baseline body weight, center, and run-in weight change. 84% CI on the
observed means shown at weeks 12, 24, and 52. Last observation carried forward;
BL = baseline; LS = least squares; CI = confidence interval.CELL METABOLISM : OCTOBER 2006
NPY5R antagonism lacks anti-obesity efficacyMK-0557-treated 5% responders with a mean difference (95%
CI) of 2.0 (0.1, 3.9) mm Hg for MK-0557-treated patients versus
placebo (p = 0.037).
Change in serum IGF-I was assessed in a subset of 364
patients. IGF-I increased until week 12 and then reached a pla-
teau; after 52 weeks of treatment, the median difference (95%
CI) between MK-0557 and placebo was 15.1% (9.0%, 21.0%)
(p < 0.001).
There were no apparent differences in clinical adverse ex-
periences between placebo and MK-0557. Serious adverse
experiences were reported in 5.0% and 3.2% of patients treated
with placebo and MK-0557, respectively. Overall, MK-0557 was
generally safe and well tolerated. A patient-accounting sum-
mary and additional data on efficacy endpoints and clinical
and laboratory adverse events can be found in Tables S8–S12.
Discussion
In recent years the increase in the prevalence of overweight and
obese adults and children has led to intensive efforts to discover
novel therapeutic agents to treat obesity. NPY was one of the
first orexigenic factors to be identified (Clark et al., 1984), and
the NPY system has long been considered a prime target for
anti-obesity drug therapy. Although a wealth of information has
accumulated over the past 20 years with regard to the role of
NPY in energy homeostasis, to our knowledge no clinical study
examining a therapeutic intervention based on the NPY system
has previously been reported. Despite the presence of generally
encouraging animal data, without such clinical studies the effi-
cacy of using the NPY system as a means to modulate body
weight cannot be determined. The clinical studies reported
herein provide novel insight into the role of the NPY5R in human
energy homeostasis as well as its utility as a target for anti-
obesity drug therapy.
The results of the MK-0557 Long-Term Weight Loss Study
strongly suggest that a highly selective NPY5R antagonist is in-
sufficient as monotherapy for anti-obesity drug therapy. While
MK-0557 displayed a favorable clinical safety profile, the degree
of weight loss observed was not clinically meaningful. Since
a modest degree of statistically significant weight loss did occur,
the results do indicate that the NPY5R is a component of energy
homeostatic pathways in humans.
The PET ligand and proof-of-concept/dose-ranging studies
provided complementary data with respect to MK-0557 dosage.
These two studies strongly suggested that the 1 mg daily dose
of MK-0557 used in the long-term study would be adequate
to test the hypothesis that NPY5R was a useful target for anti-
obesity drug therapy in humans.
The degree of weight loss after 52 weeks of treatment with
MK-0557 was significantly less than that observed for several
other weight-loss drugs. Orlistat, the intestinal lipase inhibitor,
was reported to induce a mean placebo-subtracted weight
loss of 4.4 kg at 52 weeks in the XENDOS study (Torgerson
et al., 2004). A meta-analysis of results from studies with sibutr-
amine, a serotonin, norepinephrine, and dopamine reuptake in-
hibitor, reported a 4.3 kg placebo-subtracted mean weight loss
for that agent at 52 weeks (Padwal et al., 2003). The combination
of fenfluramine and phentermine (Fen-Phen), which is often
cited as an important benchmark in the field of obesity research,
was reported to induce an 8.46 1.1 kg weight loss versus 4.46
0.9 kg weight loss for placebo at 24 weeks (placebo-subtractedCELL METABOLISM : OCTOBER 2006weight loss of approximately 4.0 kg) (Weintraub et al., 1984). A
second Fen-Phen study, which lacked a placebo arm through-
out the study period, reported an approximate 15.8 kg weight
loss at 52 weeks (Weintraub et al., 1992). However, it should
be noted that the Fen-Phen data are derived from a small in-
vestigator-initiated study and a subsequent uncontrolled study,
neither of which were formal registration trials. Therefore, the
efficacy of Fen-Phen cited herein has been questioned by some
investigators. The placebo-subtracted weight loss observed
with MK-0557 is also less than the mean 4.8 kg placebo-
subtracted weight loss observed for the 20 mg daily dose of the
cannabinoid-1 receptor inverse agonist rimonabant at 1 year, as
reported in the RIO-Europe study (Van Gaal et al., 2005).
The metabolic stability, bioavailability, safety profile, potency,
and selectivity of MK-0557 in conjunction with the observed
weight loss in animal studies made MK-0557 an attractive drug
to study clinically. Although based on animal studies it was
widely accepted that both the NPY1R and NPY5R play a role
in feeding behavior, the relative contribution of either receptor
has not been established. Some studies suggest that the
NPY1R component of the NPY system might have greater rela-
tive importance than the NPY5R in feeding behavior. A compar-
ison of NPY1R2/2 mice and NPY5R2/2 mice generated on a
similar genetic background demonstrated that NPY-induced
feeding was remarkably reduced in NPY1R2/2 mice but not in
NPY5R2/2mice (Kanatani et al., 2000). Two recent studies failed
to show an effect of highly selective NPY5R antagonists on
NPY-induced food intake, although both compounds signifi-
cantly suppressed feeding induced by selective NPY5R ago-
nists (Turnbull et al., 2002; Kanatani et al., 2006). In a chronic
study, a NPY1R antagonist significantly inhibited weight gain
in Zucker fatty rats (Ishihara et al., 2002). Hence, dominance
of the NPY1R component of the NPY system is one possible ex-
planation for our observed weight-loss results. Another potential
reason for the small clinical response to MK-0557 is that multiple
redundant pathways defend against alterations in body weight.
Compensation by another orexigenic system (or the NPY1R
component of the NPY system) may have overridden the effect
of NPY5R antagonism in patients in our clinical studies. Since
these studies only examined one component of the NPY sys-
tem, it would be premature to challenge the importance of NPY
in human feeding behavior on the basis of these results alone.
In summary, the studies described herein provide novel in-
sight into the use of the NPY5R as a sole target for the develop-
ment of an anti-obesity drug therapy. However, other chronic
diseases, such as high blood pressure or diabetes, commonly
require two or even three drugs to achieve an optimal therapeu-
tic response. It is generally accepted that significant and robust
weight-loss efficacy would require a multipronged pharmaceu-
tical solution. Nonetheless, based on the modest degree of
weight loss observed after 52 weeks of treatment, optimal com-
bination therapy would need to employ an agent that demon-
strates synergism with MK-0557.
Experimental procedures
PET tracer study
Design
The aim of this study was to determine the level of occupancy of NPY5R
in human brain following oral administration of MK-0557. The double-blind,
single oral dose, sequential, four-panel (A, B, C, and D), randomized,
placebo-controlled study had four healthy male subjects in each panel.279
A R T I C L EThe Ethics Committee at Uppsala University, Department of Obstetrics and
Gynecology approved the studies and informed consent was obtained
from all subjects. On day 1, following an overnight fast, all subjects under-
went a baseline [11C]MK-0233 PET scan at w10 AM. Following the PET
scan, at w12 noon, three subjects in each panel received a single oral
dose of MK-0557; one subject was administered a placebo dose. Panels
A, B, C, and D received 125, 5, 1.25, and 5 mg MK-0557, respectively. A sec-
ond [11C]MK-0233 PET scan was performed for panel A at 24–30 hr post-
dose, panels B and C at 24 hr post-dose, and Panel D at 120 hr post-dose.
The striatum was used as the target region to estimate NPY5R occupancy
because in vitro autoradiography studies in postmortem human brain
sections had revealed that the highest NPY5R binding is in the caudate
and putamen, whereas no specific binding was found in the cerebellum.
Measurements
PET scans were performed on an ECAT EXACT HR+ from CTI/Siemens. For
each scan, a bolus of [11C]MK-0233 was injected intravenously, simulta-
neously starting a dynamic emission scan. Emission data were acquired in
3D (retracted septa) mode; transmission data (for subsequent attenuation
correction) was acquired in 2D mode before injection of the radiopharmaceu-
tical. Emission scans were corrected for attenuation, scatter, and dead time
and reconstructed with a ramp filter, resulting in transverse and axial spatial
resolutions of approximately 5 mm at FWHM. For each subject, the baseline
and post-dosing [11C]MK-0233 PET images were aligned using the AIR pack-
age (Woods et al., 1998a, 1998b). Then, a static image was obtained from the
baseline scan by summing all frames in the dynamic PET study. Regions of
interest (ROI) were defined in the striatum (caudate and putamen) and the
cerebellum using the Montreal Neurological Institute DISPLAY software
(http://www.bic.mni.mcgill.ca/software/). ROIs were projected into the
dynamic scans and time-activity curves (TAC) were generated. TACs were
expressed in Standardized Uptake Value (SUV) using the subject body
weight and the tracer-injected dose: Activity in SUV = 1000 3 Activity in
Bq 3 Weight (kg)/Injected dose (Bq).
The tissue kinetic data were analyzed using the Logan graphical method
with the cerebellum as reference. Logan analysis estimates the relative dis-
tribution volume ratio (DVR) corresponding to the ratio between the tracer
distribution volume in the receptor-rich or target region and that of the refer-
ence region (devoid of specific binding sites). The tracer binding potential
(BP = DVR 21) was used as an index of receptor availability. Percentage
drug receptor occupancy (RO) was calculated as RO = 100 3 (1 2 BPPD/
BPbaseline), where BPbaseline and BPPD correspond to the estimated binding
potentials under baseline conditions and after drug administration, respec-
tively. All analysis programs were implemented in MATLABO` (The Math-
Works, Inc., Natick, Massachusetts).
Statistical analysis
For the 1.25 mg, 5 mg, and 125 mg doses of MK-0557 in panels A, B, and C,
respectively, the mean plasma MK-0557 concentration before and after the
time of the PET scan was computed. The plasma MK-0557 concentration
at 120 hr after the 5 mg dose in panel D was estimated by extrapolating
the concentration at the last measurable time point (44 hr) using an estimated
24 hr half-life (observed in previous studies). The mean observed striatal
NPY5R occupancy was estimated using an arithmetic mean because recep-
tor occupancy for some subjects receiving placebo was less than zero. The
relationship between receptor occupancy and plasma MK-0557 concentra-
tion was explored using a two-parameter sigmoidal Emax model (Hill equa-
tion). The model was parameterized to model the log-concentration. Various
optimization algorithms and convergence criteria were used to confirm the
fit of the model. The IC95 was estimated using this model. An implicit
assumption of the model is that there is no time dependence (hysteresis) in
the relationship between plasma drug concentration and striatal NPY5R
occupancy. This model also assumes that MK-0557 binds NPY5R with
simple 1:1 stoichiometry.
Proof-of-concept/dose-ranging study
Design
This was a multicenter, double-blind, randomized, placebo-controlled study
to demonstrate the utility of the mechanism, and to assess the dose
response, of MK-0557. Prior to randomization, there was a 6 week diet/
exercise run-in period. In the last 2 weeks of the run-in, all subjects were
administered placebo (single-blind). Subjects were then allocated to 1 of 5
treatments (plus continuing dietary/exercise intervention): placebo or 0.2,2801, 5, or 25 mg of MK-0557 daily. They were instructed to follow a 500 kcal/
day deficit in their caloric intake. Each group was treated for a period of
12 weeks followed by a 12 week off-drug period. Schulman Associates Insti-
tutional Review Board, Inc. (Cincinnati, Ohio) (an independent institutional
review board) approved the study and informed consent was obtained
from all subjects.
Subjects
Patients were between the ages of 21 and 65 years, had a BMI of 30 to
40 kg/m2, had maintained a stable weight (63 kg) for at least 3 months prior
to study start, and were judged to be in otherwise good health based on
medical history, physical examination, and routine laboratory tests. Addi-
tional demographic information can be found as Tables S2 and S3.
Statistical analysis
The primary analysis population was the MITT population, which consisted of
randomized patients who took at least one dose of study medication and had
at least one post-randomization measurement. The primary efficacy analysis
was based on the mean change from baseline (week 0) in body weight at
week 12, or to the last observed measurement for patients discontinuing
prior to week 12 (i.e., last observation carried forward [LOCF]). The cohort
of patients who completed the treatment period with no major protocol vio-
lations was also analyzed. The primary analysis was based on the mean
change from baseline (week 0) in body weight at week 12. Parametric anal-
ysis of covariance (ANCOVA) appropriate for a multicenter, parallel study
design was used to compare the treatments. For assessing the primary effi-
cacy hypothesis, the model contained factors: treatment, study center, stra-
tum (based on the weight loss observed during the run-in), and baseline body
weight. The treatment-by-center and treatment-by-strata interactions were
assessed but not included in the primary analysis. Assumptions for the anal-
ysis of covariance were checked and supportive nonparametric analyses
corroborated the primary parametric analysis. A trend-testing step-down
procedure was used to test for a monotonic trend among the 4 doses versus
placebo; individual group comparisons to placebo were also performed.
These comparisons to placebo were based on the ANCOVA model using
linear contrasts. Unless otherwise specified, least-squares means and 95%
confidence intervals based on the ANCOVA model are reported. Responders
to treatment (i.e., 5% responders) were analyzed using a logistic regression
model with similar terms as the ANCOVA. Most comorbidity-related parame-
ters (e.g., LDL, HDL, etc.) were analyzed using a ANCOVA model similar to that
described above; triglycerides and IGF-I were analyzed nonparametrically.
Adverse experiences were summarized.
Long-term weight loss study
Study design
This was a multicenter, double-blind, randomized, placebo-controlled study
to examine the safety and efficacy of MK-0557 to induce weight loss in obese
patients. The primary hypothesis was that MK-0557 was more effective than
placebo at inducing weight loss after 52 weeks of treatment.
Prior to randomization, there was a 2 week diet/exercise and single-blind
placebo run-in period. Eligible patients were allocated to treatment with pla-
cebo or MK-0557 1 mg daily plus continuing dietary/exercise counseling. The
patients were instructed to follow a 500 kcal/day deficit in their caloric intake.
The primary efficacy measurement was body weight. Secondary efficacy
measurements included waist circumference, blood pressure, fasting plasma
lipid profile (total cholesterol, HDL-C, LDL-C, non-HDL-C, TG), fasting
plasma glucose, insulin, and insulin sensitivity analyzed by quantitative insu-
lin sensitivity check index (QUICKI) (Katz et al., 2000).
Subjects
Eligible patients wereR 18 years old, BMI 30–43 kg/m2 or BMI 27–<30 kg/m2
with obesity-related comorbidities, who had maintained a stable weight for
3 months prior to screening. Patients were judged to be in good health based
on history, physical exam, and routine laboratory tests. Additional demo-
graphic information can be found as Table S8. Quorum Review Inc. (Seattle,
Washington) (an independent institutional review board) approved the study,
and informed consent was obtained from all subjects.
Statistical analysis
The primary analysis population was the MITT population, which consisted of
randomized patients who took at least one dose of study medication and had
at least one post-randomization measurement. The primary analyses was
based on the mean change from baseline in body weight at week 52, or to
the last observed measurement for patients discontinuing prior to week 52CELL METABOLISM : OCTOBER 2006
NPY5R antagonism lacks anti-obesity efficacy(i.e., LOCF). A secondary analysis population of patients who completed the
study with no major protocol violations was also analyzed. Parametric anal-
ysis of covariance (ANCOVA) with factors of treatment group, baseline body
weight, weight loss observed during the 2 week run-in, and center was used
to assess weight loss from baseline at week 52. Treatment group compari-
sons were based on the ANCOVA model using linear contrasts. Unless other-
wise specified, least-squares means and 95% confidence intervals based on
the ANCOVA model are reported. As a secondary hypothesis, the proportion
of 5% and 10% responders were analyzed using a logistic regression model
with terms for the treatment group, baseline body weight, weight loss during
the 2 week run-in, and center. The Hochberg procedure was applied to con-
trol for multiplicity of the secondary efficacy hypotheses. Most comorbidity-
related parameters (e.g., LDL-C, HDL-C, etc.) were analyzed using an
ANCOVA model similar to that described above; triglycerides and IGF-I
were analyzed nonparametrically. An interim analysis was conducted after
most patients had completed 24 weeks of treatment; an unblinded statisti-
cian who had no other responsibilities on the study or project conducted
this interim analysis. Therefore, statistical significance of the primary and
secondary hypotheses was assessed at the 0.049 level.
Supplemental data
Supplemental data include one figure and twelve tables and can be found
with this article online at http://www.cellmetabolism.org/cgi/content/full/4/
4/275/DC1/.
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